Alzinova reveals plans to start ALZ-101 study for Alzheimers disease
Category: #health  By Pankaj Singh  Date: 2020-11-06
  • share
  • Twitter
  • Facebook
  • LinkedIn

Alzinova reveals plans to start ALZ-101 study for Alzheimers disease

The development of the novel Alzheimer’s disease treatment options is among the most vital health needs across the world today. In a bid to develop therapeutic vaccine for this disease , Sweden-based Alzinova AB has reportedly announced plans to advance its vaccine candidate named ‘ALZ-101’ at the CTAD (Clinical Trials on Alzheimer's disease digital meet.

For the record, Alzinova AB is a Swedish biopharma firm focusing on the development of novel treatment options for Alzheimer's disease by aiming neurotoxic amyloid-β oligomers. The lead vaccine candidate, ALZ-101, is a unique therapeutic vaccine against the oligomeric, neurotoxic form of Aβ 1-42 and is presently in the preclinical development stage.

Alzinova AB said in a meeting that the company will conduct a Phase I study in patients with initial stage Alzheimer’s disease and is anticipated to commence during Q2 2020. This is a first-in-human clinical study, and the main objective is to evaluate the tolerability and unexpected adverse events of the ALZ-101 vaccine candidate.

The clinical will further include an evaluation of the immune response that is levels of antibodies created by the vaccine after constant dosing. The study will be commenced in Finland in collaboration with Clinical Research Services Turku - CRST Oy.

Speaking on which, Kristina Torfgård, CEO of Alzinova AB said that based on the documented pre-clinical outcomes, the company is looking forward to the development of ALZ-101 into a therapeutic vaccine for patients.

It is first of kind clinical trial that particularly targets the toxic forms of the Aβ peptide Mr. Torfgård said while adding that this is an important step in a field where the medical need is great.

The arrangements to submit the application and commence the study will continue according to plan. The main aim is to start the study during Q2 2021.

Source credit - https://www.prnewswire.com/news-releases/alzinova-ab-announces-the-study-design-for-the-first-clinical-study-with-the-oligomer-specific-therapeutic-vaccine-alz-101-at-a-scientific-congress-301166302.html



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

Canada-based CloudMD buys CMD to expand medical database
Canada-based CloudMD buys CMD to expand medical database
By Pankaj Singh

CloudMD Software & Services Inc., a virtual medical care solutions provider based in Canada, has reportedly announced that it has completed the acquisition of the Canadian Medical Directory (CMD)- the nation’...

Collier’s Medical to offer HealthySole UVC units for infection control
Collier’s Medical to offer HealthySole UVC units for infection control
By Pankaj Singh

Collier’s Medical Equipment, a leading distributor of technologically-advanced medical equipment, has reportedly inked an agreement with HealthySole. This agreement has been geared towards the delivery of Healthy...

Western Union to offer money transfer services at Walmart U.S. stores
Western Union to offer money transfer services at Walmart U.S. stores
By Pankaj Singh

Walmart, an American retail chain, and Western Union, a financial service company, have recently announced a new collaboration deal. The agreement will allow the money transfer services of Western Union to be deployed ...